Here's How Much $100 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth Today
Vertex Pharmaceuticals VRTX has outperformed the market over the past 10 years by 1.52% on an annualized basis producing an ...
Vertex Pharmaceuticals’ (VRTX) “Outperform” Rating Reaffirmed at William Blair
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by stock analysts at ...
Vertex Pharmaceuticals Sets Sight on Expanding Portfolio with Alyftrek Approval, Pain Treatment Progress, and Diabetes Trials
Vertex secures FDA approval for ALYFTREK and expands TRIKAFTA use, advances diabetes and kidney disease therapies, and ...
Vertex Pharmaceuticals: Strategic Advancements and Promising Pipeline Drive Buy Rating
Analyst Evan Seigerman of BMO Capital maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), retaining the price target of ...
Zai Lab, Vertex Pharmaceuticals announce povetacicept license agreement
Zai Lab (ZLAB) and Vertex Pharmaceuticals (VRTX) announced an exclusive collaboration and license agreement for the development and ...
Vertex Pharmaceuticals Inc. stock outperforms competitors despite losses on the day
Vertex Pharmaceuticals Inc. closed $108.22 short of its 52-week high ($519.88), which the company achieved on November 8th.
Yahoo Finance2d
Vertex Pharmaceuticals Incorporated (VRTX)
Zai Lab (ZLAB) and Vertex Pharmaceuticals (VRTX) announced an exclusive collaboration and license agreement for the development and commercialization of Vertex’s povetacicept in mainland China ...
The Pharma Letter4d
Vertex out-licenses povetacicept to Zai Lab
US biopharma Vertex Pharmaceuticals has entered an exclusive collaboration and license agreement with China’s Zai Lab for the ...
Business Wire5d
Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore
--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) today announced an exclusive collaboration and license agreement for the ...
BioPharma Dive7d
Vertex, startup Orna to partner on gene editing research
The three-year partnership is another example of Vertex’s interest in improving on Casgevy, its CRISPR medicine for sickle ...
sicklecellanemianews21h
Orna, Vertex partner on gene-editing therapies for SCD, TDT
Orna Therapeutics and Vertex will use lipid nanoparticle system to develop gene-editing therapies for people with SCD and TDT ...
Business Wire5d
Zai Lab and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore
BOSTON--(BUSINESS WIRE)--Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced an exclusive collaboration and license agreement for the ...